TABLE 4.

ORs (95% CIs) for subclinical target organ damage associated with quartile of brachial‐ankle pulse wave velocity and flow‐mediated dilation in participants ≥65 years of age

		Quartile of baPWV, cm/s					Quartile of FMD, %
		Q1	Q2	Q3	Q4	P‐for trends	Q1	Q2	Q3	Q4	P‐for trends
LVH	Model 1	1(Ref)	1.640 (1.168–2.302)	1.606 (1.144–2.253)	1.657 (1.179–2.327)	0.006	1(Ref)	1.081 (.767–1.525)	.931 (.660–1.312)	.970 (.692–1.360)	.853
	Model 2	1(Ref)	1.681 (1.171–2.413)	1.421 (.987–2.046)	1.336 (.917–1.946)	.04	1(Ref)	1.017 (.705–1.465)	.912 (.632–1.314)	1.038 (.724–1.489)	.903
	Model 3	1(Ref)	1.451 (.999–2.107)	1.315 (.901–1.919)	1.125 (.751–1.685)	.208	1(Ref)	.948 (.655–1.372)	.839 (.579–1.216)	.922 (.639–1.332)	.824
UACR	Model 1	1(Ref)	1.285 (.805–2.053)	1.678 (1.068–2.636)	3.532 (2.3131–5.396)	<.001	1(Ref)	.945 (.630–1.419)	.883 (.584–1.337)	1.087 (.732–1.613)	.779
	Model 2	1(Ref)	1.285 (.805–2.053)	1.678 (1.068–2.636)	3.532 (2.311–5.396)	<.001	1(Ref)	.960 (.638–1.445)	.860 (.567–1.305)	1.090 (.733–1.622)	.722
	Model 3	1(Ref)	1.022 (.628–1.665)	1.337 (.833–2.146)	2.393 (1.527–3.750)	<.001	1(Ref)	.883 (.583–1.336)	.793 (.520–1.210)	.962 (.642–1.442)	.71
CIMT≥ .9 mm	Model 1	1(Ref)	2.625 (1.136–6.063)	2.615 (1.132–6.041)	4.230 (1.565–11.435)	.007	1(Ref)	1.990 (.782–5.063)	1.160 (.510–2.635)	1.329 (.573–3.084)	.534
	Model 2	1(Ref)	2.632 (1.133–6.071)	2.493 (1.076–5.776)	3.972 (1.465–10.770)	.01	1(Ref)	2.073 (.812–5.289)	1.167 (.512–2.659)	1.276 (.548–2.970)	.493
	Model 3	1(Ref)	2.647 (1.141–6.141)	2.789 (1.192–6.526)	4.374 (1.596–11.986)	.006	1(Ref)	2.016 (.789–5.151)	1.139 (.499–2.602)	1.224 (.524–2.861)	.524

Abbreviations: baPWV, brachial‐ankle pulse wave velocity; CI, Confidence Interval; CIMT, carotid intima‐media thickness; FMD, flow‐mediated dilation; LVH, left ventricular hypertrophy; OR, odds ratio; UACR, urine albumin–creatinine ratio.